O'Brate A - Search Results

1

Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.

Monzó M, Rosell R, Sánchez JJ, Lee JS, O'Brate A, González-Larriba JL, Alberola V, Lorenzo JC, Núñez L, Ro JY, Martín C. Monzó M, et al. J Clin Oncol. 1999 Jun;17(6):1786-93. doi: 10.1200/JCO.1999.17.6.1786. J Clin Oncol. 1999. PMID: 10561216

2

Predictive molecular markers in non-small cell lung cancer.

Rosell R, Tarón M, O'Brate A. Rosell R, et al. Curr Opin Oncol. 2001 Mar;13(2):101-9. doi: 10.1097/00001622-200103000-00004. Curr Opin Oncol. 2001. PMID: 11224707 Review.

3

Novel approaches in the treatment of non-small-cell lung cancer.

Rosell R, Sánchez JM, Tarón M, O'Brate A, Gutiérrez JL, Monzó M, Felip E, Sánchez JJ, Alberola V. Rosell R, et al. Oncology (Williston Park). 2001 Mar;15(3 Suppl 6):52-60. Oncology (Williston Park). 2001. PMID: 11301850 Free article. Review.

4

Translational oncogenomics: toward rational therapeutic decision-making.

Rosell R, Monzo M, O'Brate A, Taron M. Rosell R, et al. Curr Opin Oncol. 2002 Mar;14(2):171-9. doi: 10.1097/00001622-200203000-00006. Curr Opin Oncol. 2002. PMID: 11880707 Review.

5

Sharing new approaches to translational research in non-small cell lung cancer.

O'Brate A, Tarón M, Gandara D, Rosell R. O'Brate A, et al. Oncologist. 2000;5(6):514-9. doi: 10.1634/theoncologist.5-6-514. Oncologist. 2000. PMID: 11110605 Free article. No abstract available.

6

Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.

Wang Y, O'Brate A, Zhou W, Giannakakou P. Wang Y, et al. Cell Cycle. 2005 Dec;4(12):1847-53. doi: 10.4161/cc.4.12.2264. Epub 2005 Dec 18. Cell Cycle. 2005. PMID: 16294009 Free PMC article.

7

Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.

Zhou J, O'brate A, Zelnak A, Giannakakou P. Zhou J, et al. Cancer Res. 2004 Dec 1;64(23):8708-14. doi: 10.1158/0008-5472.CAN-04-2538. Cancer Res. 2004. PMID: 15574781

8

The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.

Marcus AI, Zhou J, O'Brate A, Hamel E, Wong J, Nivens M, El-Naggar A, Yao TP, Khuri FR, Giannakakou P. Marcus AI, et al. Cancer Res. 2005 May 1;65(9):3883-93. doi: 10.1158/0008-5472.CAN-04-3757. Cancer Res. 2005. PMID: 15867388 Free PMC article.

9

Farnesyltransferase inhibitors reverse taxane resistance.

Marcus AI, O'Brate AM, Buey RM, Zhou J, Thomas S, Khuri FR, Andreu JM, Díaz F, Giannakakou P. Marcus AI, et al. Among authors: o brate am. Cancer Res. 2006 Sep 1;66(17):8838-46. doi: 10.1158/0008-5472.CAN-06-0699. Cancer Res. 2006. PMID: 16951201 Free PMC article.

10

Design, synthesis, and biological properties of highly potent epothilone B analogues.

Nicolaou KC, Sasmal PK, Rassias G, Reddy MV, Altmann KH, Wartmann M, O'Brate A, Giannakakou P. Nicolaou KC, et al. Angew Chem Int Ed Engl. 2003 Aug 4;42(30):3515-20. doi: 10.1002/anie.200351819. Angew Chem Int Ed Engl. 2003. PMID: 12900969 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters